Early reduction in urinary albumin excretion largely explains the therapeutic benefits of finerenone in kidney outcomes among 12,512 patients with T2D and CKD.
Meta-Analysis (n=12,512)
Placebo-controlled
Does early reduction in urinary albumin excretion mediate the therapeutic benefits of finerenone on kidney outcomes in patients with T2D and CKD?
Early reduction in urinary albumin excretion is a key mediator of the renoprotective benefits of finerenone in patients with T2D and CKD.
Finerenone improved kidney and cardiovascular outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) when coadministered with conventional renin-angiotensin system inhibitors (RASi).1 A mediation analysis using pooled data from placebo-controlled kidney and cardiovascular outcomes trials of finerenone in 12,512 patients with T2D and CKD revealed that early reduction in urinary albumin excretion largely explains finerenone’s therapeutic benefits in kidney outcomes.2
Tanaka et al. (Wed,) conducted a meta-analysis in Type 2 diabetes and chronic kidney disease (n=12,512). Finerenone vs. Placebo was evaluated on Kidney outcomes. Early reduction in urinary albumin excretion largely explains the therapeutic benefits of finerenone in kidney outcomes among 12,512 patients with T2D and CKD.